Nanozyme‐Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder‐Metastasized Tumors
Advanced Materials · 2025-10 · 37 (43)
DOI: 10.1002/adma.202511181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 14.08.2025. Verfasst von Yalong Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, P. R. China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Biomimetic Materials. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Immune‐checkpoint inhibitors (ICIs) have transformed the treatment of bladder cancer. However, inadequate immune responses restrict their clinical application. To increase the efficacy of ICIs, a nanozyme‐based intelligent biomimetic immune organelle has been developed for the treatment of metastatic bladder tumors. Initially, a reactive oxygen species (ROS)‐responsive nanozyme platform is constructed using 1,2‐Distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐Tk‐(polyethylene glycol) (DSPE‐TK‐PEG) to assemble ultrasmall p‐d orbital hybrid bimetallic rhenium (Re)‐palladium (Pd) nanozyme. The orbital hybridization between the Re and Pd atoms significantly enhances the peroxidase (POD)‐like activity of the Pd nanozyme. Additionally, the RePd nanozyme exhibits notable glutathione oxidase (GSH‐OXD)‐like activity, which reduces the clearance of ROS and enhances its capacity to induce oxidative stress. This platform is then coated with bacterial outer membrane vesicles (OMVs) engineered with PD‐L1 nanobody (nb), which form RePd@OMVs PD‐L1 nb . Upon entry into the tumor microenvironment, the RePd nanozyme is released, and the PD‐L1 nb specifically binds to the tumor cell membrane to relieve its inhibition of T cells. Moreover, RePd@OMVs PD‐L1 nb demonstrates enhanced tumor accumulation and promotes synergistic catalytic‒photothermal therapy, inducing immunogenic cell death and promoting immune activation through the release of adjuvants. Consequently, the efficacy of PD‐L1 nb is significantly improved, leading to the effective eradication of tumor cells and the inhibition of recurrence and metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, P. R. China.
- State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan,…
- State Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, P. R. China.
- Nanozyme Laboratory in Zhongyuan, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, 451163, P. R. China.
ORCID-Profile: Kelong Fan
Zitieren
APA
Wu, Y., Zhang, Y., Han, J., Jiang, Y., Chen, M., Gu, X., Jiang, W., Fan, K., & Liu, B. (2025). Nanozyme‐Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder‐Metastasized Tumors. Advanced Materials, 37(43). https://doi.org/10.1002/adma.202511181
Vancouver
Wu Y, Zhang Y, Han J, Jiang Y, Chen M, Gu X, et al. Nanozyme‐Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder‐Metastasized Tumors. Advanced Materials. 2025;37(43). doi:10.1002/adma.202511181
BibTeX
@article{Wu2025,
author = {Wu, Yalong and Zhang, Yuhan and Han, Jiansong and Jiang, Yongnan and Chen, Maolong and Gu, Xinquan and Jiang, Wei and Fan, Kelong and Liu, Bin},
title = {Nanozyme‐Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder‐Metastasized Tumors},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {43},
doi = {10.1002/adma.202511181}
}
EUVIMED